The stock seems to be forming the handle of a huge cup (and double bottom) from Aug. 2022 high to Feb 2023 high.
Price has started to diverge from the moving averages on higher TFs. Nice volume accumulation. Notice how drop to 4 got bought up quickly. It tested supply zone at 6 and continues to push higher. Now news likely to hit any day to spike it to 10 or even 13.
EQ reached top mover status as a gainer one day and a loser the following day. Thursday, EQ was up +1.49% pre-market. I predict stock moves at a steady pace toward $24 price target. EQ is a mall biotech company researching Alzheimer's medicine. Healthcare is our third-largest sector ($6.2 T). Financials ($7.53 T) ranks second and information technology...
EQ soared after news on Alziemers drug. Following the spike in volume (OBV), there is a pullback. Now, I predict a bullish rise to the $24 target. Please always do your own research. This is not advice. I'm here to learn. Thoughts?
Equillium (EQ, $26.5) was one of top quarterly gainers, jumping +795.27% to $26.5 per share. Tickeron A.I.dvisor analyzed 383 stocks in the Biotechnology Industry over the last three months, and discovered that 298 of them (77.69%) charted an Uptrend while 85 of them (22.31%) trended down. Tickeron A.I.dvisor found 51 similar cases when EQ's price went up 15%...
Clinical Trial Shows Itolizumab Reduces Mortality in Patients Hospitalized with COVID-19 Equillium shares topline results of patients treated with itolizumab in clinical trial conducted in India by partner Biocon Biocon has received emergency use approval from Drugs Controller General of India for itolizumab in the treatment of CRS in COVID-19 patients with...
equillium EQ-explodes-730%-positive-covid it is bought with the rumor and it is sold with the news “We note the trial in hospitalized COVID-19 patients was small (n=30), open-label and on top of standard of care, and little data were shared but according the Biocon/EQ press releases, the itolizumab arm did demonstrate a statistically significant benefit on...